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Letter to the EditorClC-3—AGranularAnionTransporter
Involved in Insulin Secretion?Dear Editor,
Recent reports published inCell Metab-
olism (Deriy et al., 2009; Li et al., 2009)
suggest a role for the anion transporter
ClC-3 in the secretion of insulin in pancre-
atic b cells by assisting acidification of
large dense core vesicles (LDCVs). How-
ever, these reports contradict each other
and our own recent work (Maritzen et al.,
2008) in many ways and the mechanism
by which ClC-3 influences LDCV exocy-
tosis remains, in our eyes, unclear.
Whereas the physiological importance of
ClC-3 is obvious from the severe neurode-
generation resulting from its disruption
(Stobrawa et al., 2001), its function and
localization are subject to considerable
controversy. ClC-3 most likely operates
as a Cl/H+-exchanger, but some groups
maintain that it is a Cl channel. ClC-3
resides on endosomes, synaptic vesicles,
and synaptic-like microvesicles (SLMVs),
where it may lead to luminal acidification
and chloride accumulation (Maritzen
et al., 2008; Salazar et al., 2004; Stobrawa
et al., 2001). The postulated localization of
ClC-3 to the plasma membrane and
LDCVs like those containing insulin, how-
ever, is questionable.Rather than resulting
from impaired LDCVacidification, the vari-
ableeffect on insulin secretionof theClC-3
KO might be owed to altered endosomal
trafficking or changes in other hormones.
Let us first address the differences
between the two papers in question pub-
lished by Deborah Nelson and coworkers
(Deriy et al., 2009) and Erik Renstro¨m and
colleagues (Li et al., 2009). Deriy et al. find
more than three-fold lower resting serum
insulin concentrations in ClC-3 KO mice,
whereas Li et al. report unchanged resting
insulin levels. Deriy et al. find impaired
in vitro insulin secretion only in response
to glucose and not potassium chloride,
whereas Li et al. report an almost abol-
ished response to either stimulus in the
KO. The lack of potassium response in
Deriy et al. is confusing given that these
authors report smaller depolarization-
induced capacitance jumps in the KO.
We find lower basal serum insulin in these
KO mice and increased leptin (Maritzen
et al., 2008). As leptin negatively impingeson b cell insulin secretion (Morioka et al.,
2007; Seufert, 2004), this may explain
the observed decrease in serum insulin.
Unchanged serum leptin and insulin
concentrations in b cell-specific ClC-3
KOmice consolidate this as a valid expla-
nation (data not shown). It is important to
note that in both studies WT and KO
mice display identical changes in plasma
glucose levels in response to a glucose
load (Deriy et al., 2009; Li et al., 2009).
While the above aspects of both papers
are problematic, they are not the major
focus of our letter. Our findings in chro-
maffin cells agree in principle that a loss
of ClC-3 expression can result in reduced
exocytosis and release from LDCVs (Mar-
itzen et al., 2008). Given the identical
intracellular localization of ClC-3 in chro-
maffin and b cells (Maritzen et al., 2008),
one could assume a similar effect in b cells
as was identified (Deriy et al., 2009; Li
et al., 2009). The main point of our letter,
however, concerns the proposed mecha-
nism presented in both papers claiming
that ClC-3 is significantly expressed on
LDCVs and that loss of ClC-3 reduces
insulin secretion by directly reducing
LDCV acidification and exocytosis. Both
papers lack appropriate and essential
controls required to validate the localiza-
tion data.
Localization of ClC-3 on LDCVs in Deriy
et al. is based on immunogold, with no KO
staining performed to control for antibody
specificity. These gold particles are found
everywhere (Figure 3A, Deriy et al.),
including but not exclusive to LDCVs. Pre-
absorption with excess insulin is insuffi-
cient to establish specificity, and more-
over would be unnecessary if the proper
KO controls had been carried out and
shown no labeling.
The evidence for ClC-3 localization
on LDCVs (Figures 3C–3E, Li et al.) is
also unconvincing. These authors show
enrichment of ClC-3 in a ‘‘secretory
granule’’ fraction without stating how
much protein has been loaded in either
lane. However, this apparent enrichment
might be entirely due to comparing
postnuclear supernatant (which includes
cytosolic proteins) with spun-down mem-Cell Metabolism 1branes (which are reported to be further
purified by ‘‘FACS’’ (as stated in legend)
or by immunoprecipitation (as stated in
text on page 313)). The lower lanes in this
figure contain no band whatsoever in the
‘‘SG fraction’’ and therefore fail to prove
enrichment of LDCV proteins. Figure 3D
of Li et al. quite remarkably shows only
a single vesicle. Li et al. state that >95%
of vesicles, preselected as positive for
both ClC-3 and phogrin (n = 26 vesicles),
are also positive for insulin. This statement
seemingly provides statistical support for
a localization of ClC-3 on LDCVs, a major
conclusion of this and previously pub-
lished work (Barg et al., 2001). However,
such a finding is trivial because phogrin-
eGFP and insulin should colocalize to
more than 90% if the phogrin labeling is
LDCV specific. The authors should rather
have stated the percentage of LDCVs
containingClC-3, or ofClC-3positive vesi-
cles (not just the fraction sorted for phog-
rin) containing insulin or phogrin. The
single vesicle shown has adjacent, not
overlapping, staining for ClC-3 with either
insulin or phogrin. This becomes relevant
when one studies their immuno-EM data
containing one large vesicle attached to
several smaller vesicles (Figure 3E, Li
et al.). Thus, ClC-3 may be expressed on
the small vesicles adjacent to the large
vesicle, potentially explaining the strange
fluorescence localization data in Figure
3D in Li et al. (2009). The fact that
several vesicles areattached to eachother
invalidates their approach(es) used to
‘‘purify’’ LDCVs. This immuno-EM data
allegedly used both 25 nm (ClC-3) and
5 nm (insulin) diameter gold particles,
but black particles (of unknown size due
to lack of scale reference) of one only
size can be identified. Therefore, this
picture fails to provide evidence for any
colocalization.
No KO controls are shown for their im-
muno-EM, and the antibody used is not
specified. These authors have previously
published work (Barg et al., 2001) using
the Nelson group ClC-3 antibody that
also stained KO tissue in our hands (Mar-
itzen et al., 2008). Li et al. also had access
to our own KO-controlled antibody (Marit-
zen et al., 2008). However, this antibody
has not been tested by us for suitability
in immuno-EM experiments, and Li et al.
provide no evidence suggesting these
authors have either. Their analysis of the
gold particle density (Figure S3, Li et al.)2, October 6, 2010 ª2010 Elsevier Inc. 307
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cles also on mitochondria, which do not
express ClC-3, arguing against the spec-
ificity of their labeling.
Given that both groups had ClC-3 KO
mice, we wonder why the simple but
entirely essential KO controls of antibody
experiments were not reported. Neither
publication (Deriy et al., 2009; Li et al.,
2009) provides, in our view, clear and
convincing evidence for a localization of
ClC-3 on LDCVs. This is a major point of
both papers and the basis for their
hypotheses on how loss of ClC-3 affects
insulin secretion. An alternative mecha-
nism has not yet been identified but
the hypothesis remains that the lack of
ClC-3 directly or indirectly affects other
trafficking and sorting events in these
cells. We show with isolated islets and
INS-1 cells that ClC-3 does not copurify
with insulin or other LDCV markers, but
localizes to SLMVs and endosomes in
these cells and in chromaffin and PC12
cells (Maritzen et al., 2008).
We write this letter in the hope of iden-
tifying potential problems with the308 Cell Metabolism 12, October 6, 2010 ª20hypothesis put forward by these authors
(Deriy et al., 2009; Li et al., 2009) that
ClC-3 directly acts on LDCVs to affect
insulin secretion. Our wish here is to at
least draw attention to insufficient evi-
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